Serum metabolomics as a novel diagnostic approach for pancreatic cancer

Metabolomics

Volumn 6, Issue 4, 2010, Pages 518-528

  Nishiumi, Shin ^a   Shinohara, Masakazu ^a   Ikeda, Atsuki ^a   Yoshie, Tomoo ^a   Hatano, Naoya ^a   Kakuyama, Saori ^a   Mizuno, Shigeto ^b   Sanuki, Tsuyoshi ^a   Kutsumi, Hiromu ^a   Fukusaki, Eiichiro ^c   Azuma, Takeshi ^a   Takenawa, Tadaomi ^a   Yoshida, Masaru ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

GC MS; Metabolomics; Pancreatic cancer; PCA; PLS DA

Indexed keywords

IVA;

EID: 78649334462     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-010-0224-9     Document Type: Article

References (17)

1. Bory, C., Boulieu, R., Chantin, C., & Mathieu, M. (1990). Diagnosis of alcaptonuria: rapid analysis of homogentisic acid by HPLC. Clinica Chimica Acta, 189, 7-11.
2. Ching, C. K., & Rhodes, J. M. (1989). Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer. British Journal of Cancer, 59, 949-953.
3. Dettmer, K., Aronov, P. A., & Hammock, B. D. (2007). Mass spectrometry-based metabolomics. Mass Spectrometry Reviews, 26, 51-78.
4. Hibi, T., Mori, T., Fukuma, M., et al. (2009). Synuclein-γ is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer. Clinical Cancer Research, 15, 2864-2871.
5. Hirayama, A., Kami, K., Sugimoto, M., et al. (2009). Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Research, 69, 4918-4925.
6. Jemal, A., Siegel, R., Ward, E., et al. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225-249.
7. Lokhov, P. G., Dashtiev, M. I., Moshkovskii, S. A., & Archakov, A. I. (2010). Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics, 6, 156-163.
8. Marescau, B., De Deyn, P. P., & Holvoet, J. (1995). Guanidino compounds in serum and urine of cirrhotic patients. Metabolism, 44, 584-588.
9. Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001). Estimating the world cancer burden: Globocan 2000. International Journal of Cancer, 94, 153-156.
10. Rosty, C., & Goggins, M. (2002). Early detection of pancreatic carcinoma. Hematology/Oncology Clinics of North America, 16, 37-52.
11. Sitek, B., Sipos, B., Alkatout, I., et al. (2009). Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation. Journal of Proteome Research, 8, 1647-1656.
12. Sreekumar, A., Poisson, L. M., Rajendiran, T. M., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457, 910-914.
13. Uehara, H., Nakaizumi, A., Tatsuta, M., et al. (1999). Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: Comparison with K-ras mutations. American Journal of Gastroenterology, 94, 2513-2518.
14. Valenza, F., Aletti, G., Fossali, T., et al. (2005). Lactate as a marker of energy failure in critically ill patients: hypothesis. Critical Care, 9, 588-593.
15. Xue, R., Lin, Z., Deng, C., et al. (2008). A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry, 22, 3061-3068.
16. Yokoyama, M., Ochi, K., Ichimura, M., et al. (2002). Matrix metalloproteinase-2 in pancreatic juice for diagnosis of pancreatic cancer. Pancreas, 24, 344-347.
17. Yu, K. H., Barry, C. G., Austin, D., et al. (2009). Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. Journal of Proteome Research, 8, 1565-1576.